MedTrace Logo

A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

NCT05958199 · Status: SUSPENDED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 131

Last updated 2025-06-27

No results posted yet for this study

Summary

NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors. The goal of this clinical trial is to learn whether NPX267 is safe and tolerable in patients whose cancers are known to express HHLA2 including epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer. The main questions it aims to answer are:

* what is an appropriate dose to be given to patients?
* are the side effects of treatment manageable?

Participants will be evaluated for participation in the study. Patients who are treated will receive an intravenous infusion of NPX267 every three weeks if their disease has not progressed. Patients will be closely monitored by the treating physician.

Conditions

  • Metastatic Malignant Neoplasm

Interventions

DRUG

NPX267

NPX267 will be administered by intravenous infusion every three weeks until documented disease progression or participant withdrawal

Sponsors & Collaborators

  • NextPoint Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Leena Gandhi, MD, PhD · NextPoint

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-21
Primary Completion
2025-09-20
Completion
2025-09-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05958199 on ClinicalTrials.gov